Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 87.11% is in line with its 5-year average of 89.81%, near the low end of its 5-year range (85.08%–92.81%).
0.34% above its 12-month average of 86.82%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 85.08%.
GROSS MARGIN
87.11%
GROSS MARGIN AVG TTM
86.82%
GROSS MARGIN AVG 3Y
89.21%
GROSS MARGIN AVG 5Y
89.81%
GROSS MARGIN AVG 10Y
84.44%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.34%
CURRENT VS 3Y AVG
-2.35%
CURRENT VS 5Y AVG
-3.01%
CURRENT VS 10Y AVG
+3.16%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+110.51%
vs the sector median at left
Ocular Therapeutix, Inc.
Market Cap
$1.61B
Gross Margin
87.11%
TTM Avg
86.82%
3Y Avg
89.21%
5Y Avg
89.81%
Market Cap
$1.62B
Gross Margin
66.15%
TTM Avg
69.48%
3Y Avg
67.43%
5Y Avg
67.56%
Market Cap
$1.63B
Gross Margin
51.01%
TTM Avg
55.14%
3Y Avg
57.28%
5Y Avg
56.79%
Market Cap
$1.59B
Gross Margin
53.89%
TTM Avg
45.92%
3Y Avg
-11.61%
5Y Avg
-9.29%
Market Cap
$1.57B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
66.67%
Market Cap
$1.54B
Gross Margin
97.47%
TTM Avg
96.23%
3Y Avg
48.12%
5Y Avg
65.41%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ocular Therapeutix, Inc. (OCUL) | $1.61B | 87.11% | 86.82% | 89.21% | 89.81% |
| Septerna Inc (SEPN)vs › | $1.61B | 99.57% | 100.00% | 75.00% | 75.00% |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 44.77% | 42.62% | 43.56% | 44.93% |
| uniQure N.V. (QURE)vs › | $1.60B | 89.53% | 60.98% | 58.20% | 16.96% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | 66.15% | 69.48% | 67.43% | 67.56% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 51.01% | 55.14% | 57.28% | 56.79% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | 53.89% | 45.92% | -11.61% | -9.29% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | 100.00% | 100.00% | 100.00% | 66.67% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | 97.47% | 96.23% | 48.12% | 65.41% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 73.09% | 81.06% | 86.06% | 90.71% |
Gross Margin
87.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 85.08% |
| 2026-03-31 | 87.68% |
| 2025-12-31 | 87.97% |
| 2025-09-30 | 87.80% |
| 2025-06-30 | 85.56% |
| 2025-03-31 | 88.20% |
| 2024-12-31 | 92.80% |
| 2024-09-30 | 89.88% |
| 2024-06-30 | 90.82% |
| 2024-03-31 | 91.02% |
| 2023-12-31 | 90.64% |
| 2023-09-30 | 90.87% |
| 2023-06-30 | 91.41% |
| 2023-03-31 | 90.92% |
| 2022-12-31 | 92.81% |
| 2022-09-30 | 91.03% |
| 2022-06-30 | 90.58% |
| 2022-03-31 | 90.14% |
| 2021-12-31 | 91.00% |
| 2021-09-30 | 89.22% |
| 2021-06-30 | 90.65% |
| 2021-03-31 | 87.85% |
| 2020-12-31 | 90.75% |
| 2020-09-30 | 92.34% |
| 2020-06-30 | 91.46% |
| 2020-03-31 | 68.61% |
| 2019-12-31 | 62.81% |
| 2019-09-30 | 2.77% |
| 2019-06-30 | 15.08% |
| 2019-03-31 | 73.98% |
| 2018-12-31 | 76.79% |
| 2018-09-30 | 76.91% |
| 2018-06-30 | 76.39% |
| 2018-03-31 | 76.47% |
| 2017-12-31 | 76.80% |
| 2017-09-30 | 76.10% |
| 2017-06-30 | 76.26% |
| 2017-03-31 | 75.79% |
| 2016-12-31 | 75.15% |
| 2016-09-30 | 76.52% |
| 2016-06-30 | 76.19% |
| 2016-03-31 | 78.38% |
| 2015-12-31 | 78.90% |
| 2015-09-30 | 78.79% |
| 2015-06-30 | 82.57% |
| 2015-03-31 | 86.85% |
| 2014-12-31 | 94.06% |
| 2014-09-30 | 77.62% |
| 2014-06-30 | 79.38% |
| 2014-03-31 | 66.67% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
